Background: Preclinical models suggest that MAPK pathway is implicated in the immune-resistance of tumors and MEK-inhibition can increase the CD8+ T-cell infiltration and the efficacy of PD-1/PD-L1 blockade. Methods: First, we evaluated PD-L1 mRNA expression by Real Time qPCR and its protein production, togheter with MAPK proteins in a panel of non-small cell lung cancer (NSCLC) cell lines. Then, we studied the changes in PD-L1 and major histocompatibility complex class-I (MHC-I) expression and cytokines' production, after inhibition with selumetinib or stimulation of MAPK signalling by phorbol 12-myristate 13-acetate (PMA). In addition, we explored the effect of MEK inhibition on T-cell function by using Peripheral blood mononuclear cells (PBMC) from healthy volunteers. Results: A consistent correlation between PD-L1 mRNA and protein expression across cell lines suggested that expression mainly depends on trascriptional regulation, and it is regulated by MAPK signal, through the bindng of p65 to the PD-L1 promoter. Moreover, MEK inhibition resulted in an increased expression of MHC-I on cancer cells and increased mRNA expression levels of IFN gamma, IL-6, IL-1B, and TNFalpha, all molecules involved in the activation and differentiation of TCD8+ cytotoxic lymphocytes (CTL) subset. In this scenario, we also tested the effect of MEK inhibitor on activated T-lymphocytes from PBMC of healthy volunteers. After five days of treatment, RT-qPCR analysis revealed a significant increase of mRNA expression of some typical CD8+ T cell pro-inflammatory cytokines, like IL-12, TNFalpha and IFNgamma. Conclusions: These results further support the idea that MEK inhibitor reduces PD-L1 expression and this allows the establishment of a pro inflammatory microenvironment. On the other side, pheripheral T cells, treated with selumetinib, produce pro inflammatory cytokines typical of CTL subset, that seems more involved in immune response against cancer. In this context, MEK inhibition may represent a potential mechanism to convert otherwise resistant cancers and suggest new potential treatment combination strategies of MEK-inhibitors with anti-PD-L1 antibodies in NSCLC. Legal entity responsible for the study: University of Campania "L. Vanvitelli" Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.
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EGFR clonality and tumor mutation burden (TMB) analysis based on circulating tumor DNA (ctDNA) sequencing in advanced non-small cell lung cancer (NSCLC) Background: TKI has significantly improved survival time of NSCLC pts with sensitive mutation. However, pts present different outcome while receiving TKI treatment. We conduct a prospective multicenter clinical trial to determine whether clonality of sensitive mutation is related to the efficacy of TKI. We also evaluate the consistency of TMB between tissue and blood in this cohort. Methods: Paired tumor and plasma samples at diagnosis were obtained from systemic treatment naïve pts with advanced NSCLC. DNA was sequenced by target-capture deep sequencing of 1021 previously annotated genes related to solid tumors. Clonal EGFR mutation was defined if EGFR mutation was in the cluster with the highest mean variated allele frequency with PyClone, and otherwise subclonal EGFR mutation. TMB of tissue (tTMB) and blood (bTMB) analysis interrogated single nucleotide variants, small insertion and deletion, with VAF ≥3% and ≥0.5%, respectively. TMB-high pts were identified with ≥9 mut/MB (upper quartile of data from geneplus). Results: During February to November 2017, 80 advanced NSCLC pts were enrolled from 9 centers. A total of 371 somatic variations were detected in tissues. Mutations occurred most frequently in TP53 (52%), EGFR (47%), ALK (13%), KRAS (11%). In matched plasma, 258 (70%) tumor-derived mutations were detected by pan-caner panel sequencing. A total of 41 EGFR mutations were detected in 37 pts, most of which occurred in tyrosine kinase domain (Ex19del, 42%; L858R, 37%). Most EGFR mutation were clonal in tissue and plasma, with a consistence of 85% in paired samples. In addition, bTMB was significantly correlated to tTMB (Pearson r = 0.75, p-value = 2.3e-12), with a consistence of 90%. Interestingly, high TMB was observed in a small fraction of patients (6%) with driver mutations, such as mutations in EGFR, ALK fusion, ERBB2 and PIK3CA. Conclusions: Deep sequencing with the pan-cancer panel can effectively detect mutations and evaluate TMB in both tissue and blood with high consistence. EGFR mutations can be clonal or subclonal in both tissue and blood. Prospective multicenter study is ongoing to determine the EGFR clonality as a predictive factor for the TKI efficacy in NSCLC (TRACELib-NSCLC Background: Lung cancer, one of the most frequent cancers worldwide has long relied on molecular testing of major biomarkers such as EGFR/ALK. Achieving superior clinical outcomes needs a comprehensive emphasis beyond contemporary EGFR and ALK. Several technologies arose in par with molecular testing for EGFR/ALK, most of them failing to comprehend beyond due to a universal skepticism among clinicians though recommended in NCCN guidelines. Methods: A total 137 lung cancer cases from NGS tested data (PositiveSelect) comprising 91 males and 46 females were investigated. EGFR, ALK positivity were used for data dichotomization to understand therapeutic utility of rare alterations beyond EGFR/ALK. Results: Upon dichotomization, 28% were identified with EGFR + ALK variants favoring direct EGFR/ALK targeted therapeutics. The remaining 72% harbored no EGFR/ALK variants descending into the category of chemotherapy in current clinical practice. Similarly, 23% harbored EGFR variants carrying the beneficial effects of EGFR TKIs and remaining 77% displayed no EGFR variants sloping towards chemotherapy. The study conquered the incompetence of targeted drug utilization on conventional diagnosis of EGFR/ALK in (EGFR) and (EGFR + ALK) negative cohorts. Based on our analysis of EGFR negative cohort, we identified clinically actionable variants in KRAS (7%), BRAF (2%), ERBB2 (1%), MET (2%) and RET (3%) expressing potential for targeted therapy excepting EGFR TKIs. Correspondingly, KRAS (6%), ERBB2 (1%), MET (1%) and RET (3%) variants were identified in EGFR + ALK negative cohort enabling the utility of targeted therapeutics apart from EGFR/ALK. Only 35% of the two negative limbs were categorized into chemotherapy which would have been entire cohort otherwise. Conclusions: The study accentuates the potential of comprehensive genomics in ascertaining the hallmarks of lung cancer beyond EGFR/ALK dichotomy also liaising between theory and utilization of broad spectrum genomic testing among medical professionals to circumvent chemotherapy. Thus, chemotherapy dependence in EGFR/ALK negative cohort could be effectively curtailed by clinicians evidencing better clinical outcomes. Legal entity responsible for the study: Positive Bioscience Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.
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Epidermal growth factor receptor expression (EGFR) in serum as a marker of treatment response and survival in advanced squamous cell lung cancer Background: Reliable biomarkers are needed to prognostigate patients with advanced lung cancer following chemotherapy. This study evaluated the association of serum EGFR expression with disease severity and treatment response in advanced Squamous cell lung cancer. Methods: Newly diagnosed subjects with advanced Squamous cell lung cancer (stage IIIB and IV) were
